CoChat

Pemafibrate: First Global Approval

Blair, Hannah A. · 2017 · Drugs

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Pemafibrate (Parmodia®) is a novel, highly selective peroxisome proliferator-activated receptor (PPAR)-α modulator (SPPARM). It acts by binding to PPAR-α and regulating the expression of target genes that modulate lipid metabolism, thereby decreasing plasma triglyceride levels and increasing high-density lipoprotein cholesterol levels. Developed by Kowa Company, Ltd., oral pemafibrate has been approved in Japan for the treatment of hyperlipidaemia (including familial hyperlipidaemia). This article summarizes the milestones in the development of pemafibrate leading to this first global approval for hyperlipidaemia.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-017-0818-x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 9 references

Research works printed but not linked: 5

  1. Yamashita S, Ishibashi S, Arai H, et al. Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on postprandial hyperlipidemia in dyslipidemic patients: a randomized cross-over study [abstract no. P5891]. Eur Heart J. 2016;37(Suppl 1):1204.
  2. Yamashita S, Ishibashi S, Arai H, et al. Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on cholesterol efflux from macrophages in dyslipidemic patients [abstract no. P5982]. Eur Heart J. 2015;36(Suppl. 1):1047–8.
  3. Araki E, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARα modulator (SPPARMα), on lipid and glucose metabolism in fasting and postprandial states in type 2 diabetic patients with dyslipidaemia [abstract no. 1112]. Diabetologia. 2016;59(Suppl. 1):S531.
  4. Kastelein JJP, Senko Y, Hounslow N, et al. K-877, a selective PPAR alpha modulator (SPPARM alpha), ameliorates dyslipidaemia in patients with well-controlled LDL cholesterol levels on statin therapy, without increases in serum creatinine [abstract no. P5983]. Eur Heart J. 2015;36(Suppl. 1):1048.
  5. Kastelein JJP, Senko Y, Hounslow N, et al. K-877, a selective PPAR alpha modulator (SPPARM alpha), improves dyslipidaemia in statin-treated patients with type 2 diabetes mellitus [abstract no. P5985]. Eur Heart J. 2015;36(Suppl. 1):1048.

Cited by

See all 55

Metadata

Authors
Blair, H. A.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
Blair, Hannah A.
Venue
Drugs
Published
2017-09-19
Volume
77
Issue
16
Pages
1805-1810
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W2755428798
Cited by
54
References
9
Citations by year
2026: 2 · 2025: 11 · 2024: 4 · 2023: 7 · 2022: 7 · 2021: 7 · 2020: 3 · 2019: 8 · 2018: 4 · 2017: 1
FWCI
1.79
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords
pemafibrate, hyperlipidemia, lipid metabolism, triglyceride lowering, HDL cholesterol, drug development, regulatory approval
MeSH terms
Benzoxazoles, Butyrates, Humans, Hyperlipidemias, Lipoproteins, HDL, Cholesterol, HDL, Protein Binding, Drug Approval, PPAR alpha, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pemafibrate: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-017-0818-x
The paper
Blair, H. A. (2017). Pemafibrate: First Global Approval. Drugs. https://doi.org/10.1007/s40265-017-0818-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.